ArticleCureus2025
Immune-Mediated Thrombocytopenia Induced by Niraparib: A Clinically Relevant Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A retrospective analysis of adverse drug reaction case reports for PARP inhibitors: a comparative study of olaparib and niraparib.Frontiers in pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated thrombocytopenia secondary to niraparib is very rare; pharmacovigilance signals are scarce, and the true incidence is unknown. We report a 64-year-old woman, negative for BRCA pathogenic variants, with stage IIIC high-grade serous carcinoma of the ovary, fallopian tube and peritoneum, who started maintenance niraparib 300 mg/day after neoadjuvant chemotherapy and cytoreduction surgery. Platelets fell to grade 1 in week 1 and grade 2 in week 2, leading to interruption. One week later, she presented with grade 4 thrombocytopenia (2×10^3/µL) and petechiae. There was no anaemia or other cytopenias; smear showed no schistocytes; coagulation, direct antiglobulin test and viral serologies were negative. Dexamethasone 40 mg/day for four days restored counts. Re-challenge at 200 mg/day reproduced grade 2 thrombocytopenia by week 2 and again resolved with steroids; niraparib was permanently discontinued. One year post-surgery, she remains without recurrent thrombocytopenia or disease progression. This pattern supports an immune mechanism and underscores the need for steroid therapy and withdrawal.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.